Kinase array design, back to front: Biaryl amides

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 19, 2008, Pages 5285-5289

  Baldwin, Ian ^a   Bamborough, Paul ^a   Haslam, Claudine G ^a   Hunjan, Suchete S ^a   Longstaff, Tim ^a   Mooney, Christopher J ^a   Patel, Shila ^a   Quinn, Jo ^a   Somers, Don O ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

cFMS; Inhibitors; Kinase array design; p38 MAP kinase; p38a; Structure based drug design

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMIDE; CYCLIN DEPENDENT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 4; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 14; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; POLO LIKE KINASE 1; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PROTEIN CFMS; PROTEIN KINASE LCK; PURINE; RAF PROTEIN; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CRYSTAL STRUCTURE; DISTRIBUTION VOLUME; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HYDROGEN BOND; IC 50; NONHUMAN; PHARMACOPHORE; RAT;

ADENOSINE TRIPHOSPHATE; AMIDES; ANIMALS; COMBINATORIAL CHEMISTRY TECHNIQUES; CRYSTALLOGRAPHY, X-RAY; HETEROCYCLIC COMPOUNDS, 1-RING; INHIBITORY CONCENTRATION 50; MITOGEN-ACTIVATED PROTEIN KINASE 14; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 52049086906     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.08.051     Document Type: Article

References (17)

1. Lai J., Langston S., Adams R., Beevers R., Boyce R., Burckhardt S., Cobb J., Ferguson Y., Figueroa E., Grimster N., Henry A., Khan N., Jenkins K., Jones M., Judkins R., Major J., Masood A., Nally J., Payne H., Payne L., Raphy G., Raynham T., Reader J., Reader V., Reid A., Ruprah P., Shaw M., Sore H., Stirling M., Talbot A., Taylor J., Thompson S., Wada H., and Walker D. Med. Res. Rev. 25 (2005) 310
2. Birault V., Harris J., Le J., Lipkin M., Nerella R., and Stevens A. Curr. Med. Chem. 13 (2006) 1735
3. Prien O. ChemBioChem 6 (2005) 500
4. Schindler T., Bornmann W., Pellicena P., Miller W., Clarkson B., and Kuriyan J. Science 289 (2000) 1938
5. Pargellis C., Tong L., Churchill L., Cirillo P., Gilmore T., Graham A., Grob P., Hickey E., Moss N., Pav S., and Regan J. Nat. Struct. Biol. 9 (2002) 268
6. Regan J., Breitfelder S., Cirillo P., Gilmore T., Graham A., Hickey E., Klaus B., Madwed J., Moriak M., Moss N., Pargellis C., Pav S., Proto A., Swinamer A., Tong L., and Torcellini C. J. Med. Chem. 45 (2002) 2994
7. Angell R., Aston N., Bamborough P., Buckton J., Cockerill S., deBoeck S., Edwards C., Holmes D., Jones K., Laine D., Patel S., Smee P., Smith K., Somers D., and Walker A. Bioorg. Med. Chem. Lett. 15 (2008) 4428
8. Angell R., Angell T., Bamborough P., Bamford M., Chung C., Cockerill S., Flack S., Jones K., Laine D., Longstaff T., Ludbrook S., Pearson R., Smith K., Smee P., Somers D., and Walker A. Bioorg. Med. Chem. Lett. 15 (2008) 4433
9. Jacobs M.D., Caron P.R., and Hare B.J. Proteins 70 (2008) 1451
10. b) Dewar A.L., Cambareri A.C., Zannettino C.W., Miller B.L., Doherty K.V., Hughes T.P., and Lyons A.B. Blood 105 (2005) 3127
11. A sub-set of a small-molecule X-ray crystal structure database (Allen, F.; Acta Cryst., 2002, B58, 380) was converted into Catalyst format (Accelrys Inc.) and searched using a 3D pharmacophore query built using the X-ray complex of 2 in p38α. Molecules hitting the query were processed to retain only the subgraphs containing the query features. These were converted into a 2D SMARTS representation (Daylight Chemical Systems Inc.) with generic atoms and bonds, with the exception of the hinge H-bond acceptor atom and an attachment Br or I atom replacing the tolyl ring of the query. The SMARTS queries were then used to search the GSK database for available reagents, which were examined and filtered by eye.
12. 3a.
13. 3a The final R-factor achieved for each complex was 17.2% for compound 6a and 16.9% for compound 19b. The coordinates have been deposited in the PDB as entries 3E92 and 3E93. Figures were produced using Pymol (DeLano, W.L., DeLano Scientific, Palo Alto CA, USA. http://www.pymol.org).
14. Angell R., Bamborough P., Cleasby A., Cockerill S., Jones K., Mooney C., Neu M., Somers D., and Walker A. Bioorg. Med. Chem. Lett. 18 (2008) 318 and references therein
15. McDonald O.B., Chen W., Ellis B., Hoffman C., Overton L., Rink M., Smith A., Marshalland C., and Wood E. Anal. Biochem. 268 (1999) 318
16. Wilhelm S., Carter C., Lynch M., Lowinger T., Dumas J., Smith R., Schwartz B., Simantov R., and Kelley S. Nat. Rev. Drug Discov. 5 (2006) 835
17. Pharmacokinetic parameters derived from a composite blood sampling profile in male Lewis rats were determined following intravenous (iv) and oral (po) administration at 1 mg/kg. Compound was administered as a solution in 10% DMSO/70% PEG200/20% water. Blood was collected over a 12 h time period. Plasma preparation, sample analysis and data generation were carried out as described in Ref. 3a.